Human Amniotic Fluid Mesenchymal Stem Cells from Second- and Third-Trimester Amniocentesis: Differentiation Potential, Molecular Signature, and Proteome Analysis

<div>Phenotypical characteristics of AF-MSCs from late trimesters. (a) Representative image of spindle-shaped MSCs at passage 4. (b) Expression of cell surface markers from representative FACS histograms of isotype negative controls and (c) AF-MSCs gated for CD34, CD44, CD90, and CD105. (d) The relative expression of pluripotency markers Oct-4, Nanog, Sox-2, and Rex-1 in AF-MSCs populations obtained from amniocentesis samples of second- and third-trimester at passages 4–6 by RT-qPCR. The expression of mRNA was normalized to GAPDH.</div>

Stem Cells International

fig2

Figure 2

Figure 2: Human Amniotic Fluid Mesenchymal Stem Cells from Second- and Third-Trimester Amniocentesis: Differentiation Potential, Molecular Signature, and Proteome Analysis 

Figure 2 | Human Amniotic Fluid Mesenchymal Stem Cells from Second- and Third-Trimester Amniocentesis: Differentiation Potential, Molecular Signature, and Proteome Analysis 